Top-Rated StocksTop-RatedNASDAQ:JANX Janux Therapeutics (JANX) Stock Price, News & Analysis $24.00 +0.69 (+2.96%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$24.24 +0.25 (+1.02%) As of 10/3/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Janux Therapeutics Stock (NASDAQ:JANX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Janux Therapeutics alerts:Sign Up Key Stats Today's Range$23.32▼$24.5950-Day Range$21.77▼$25.5552-Week Range$21.73▼$71.71Volume824,135 shsAverage Volume757,680 shsMarket Capitalization$1.44 billionP/E RatioN/ADividend YieldN/APrice Target$78.31Consensus RatingModerate Buy Company Overview Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX. Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration. By activating key pathways of the innate immune response, these candidates aim to recruit and amplify antitumor T-cell activity while minimizing systemic exposure. Janux’s pipeline is advancing through early-stage clinical trials to evaluate safety, tolerability and preliminary signals of efficacy in a variety of solid tumors. Based in San Diego, Janux leverages collaborations with contract research organizations and academic centers to support manufacturing and clinical development. The company’s leadership team comprises experienced immuno-oncology researchers and drug developers with backgrounds in biologics, formulation science and regulatory strategy. Janux continues to build its infrastructure and partnerships to accelerate the translation of its TLR agonists from preclinical research into potential new treatment options for cancer patients.AI Generated. May Contain Errors. Read More Janux Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreJANX MarketRank™: Janux Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 643rd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingJanux Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 13 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialJanux Therapeutics has a consensus price target of $78.31, representing about 226.3% upside from its current price of $24.00.Amount of Analyst CoverageJanux Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Janux Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.38) to ($2.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Janux Therapeutics is -13.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Janux Therapeutics is -13.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJanux Therapeutics has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Janux Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.35% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Janux Therapeutics has recently increased by 3.11%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJanux Therapeutics does not currently pay a dividend.Dividend GrowthJanux Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.35% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Janux Therapeutics has recently increased by 3.11%, indicating that investor sentiment is decreasing. News and Social Media2.5 / 5News Sentiment0.51 News SentimentJanux Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Janux Therapeutics this week, compared to 6 articles on an average week.Search Interest23 people have searched for JANX on MarketBeat in the last 30 days. This is an increase of 475% compared to the previous 30 days.MarketBeat Follows7 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Janux Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of Janux Therapeutics is held by insiders.Percentage Held by Institutions75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Janux Therapeutics' insider trading history. Receive JANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JANX Stock News HeadlinesAnalysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $78.31October 4 at 2:57 AM | americanbankingnews.comBarclays Initiates Coverage of Janux Therapeutics (JANX) with Overweight RecommendationSeptember 17, 2025 | msn.comYour Chance Before Wall Street MovesBy the time Wall Street analysts catch on, the biggest gains are usually gone. The real profits often happen before the IPO, when private investors are buying in at a fraction of the price. Our new report, From Private to Public: How To Invest In Companies Before They IPO, shows you how to identify these deals and evaluate if they’re worth the risk.October 5 at 2:00 AM | Darwin (Ad)Janux Therapeutics initiated with an Overweight at BarclaysSeptember 16, 2025 | msn.comTruist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PTSeptember 15, 2025 | msn.comJanux Therapeutics initiated with a Buy at TruistSeptember 11, 2025 | msn.comTruist Securities Initiates Coverage of Janux Therapeutics (JANX) with Buy RecommendationSeptember 11, 2025 | msn.comJanux Therapeutics resumed with a Buy at StifelSeptember 10, 2025 | msn.comSee More Headlines JANX Stock Analysis - Frequently Asked Questions How have JANX shares performed this year? Janux Therapeutics' stock was trading at $53.54 at the beginning of 2025. Since then, JANX shares have decreased by 55.2% and is now trading at $24.00. How were Janux Therapeutics' earnings last quarter? Janux Therapeutics, Inc. (NASDAQ:JANX) issued its earnings results on Thursday, August, 7th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.07. When did Janux Therapeutics IPO? Janux Therapeutics (JANX) raised $152 million in an initial public offering (IPO) on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager. How do I buy shares of Janux Therapeutics? Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Janux Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Janux Therapeutics investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), Waste Connections (WCN) and AU Optronics (AUOTY). Company Calendar Last Earnings8/07/2025Today10/05/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JANX CIK1817713 Webwww.januxrx.com Phone858-751-4493FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Janux Therapeutics$78.31 High Price Target$200.00 Low Price Target$41.00 Potential Upside/Downside+226.3%Consensus RatingModerate Buy Rating Score (0-4)2.94 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($1.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$68.99 million Net MarginsN/A Pretax Margin-24,064.01% Return on Equity-11.48% Return on Assets-11.01% Debt Debt-to-Equity RatioN/A Current Ratio47.03 Quick Ratio47.03 Sales & Book Value Annual Sales$10.59 million Price / Sales136.18 Cash FlowN/A Price / Cash FlowN/A Book Value$19.49 per share Price / Book1.23Miscellaneous Outstanding Shares60,090,000Free Float55,226,000Market Cap$1.44 billion OptionableOptionable Beta2.82 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:JANX) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.